Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rotavirus VP7 is a calcium-stabilized trimeric glycoprotein forming the outermost layer of the rotavirus capsid with T=13 icosahedral symmetry, capping VP6 pillars on the double-layered particle (DLP). It displaces the transient ER membrane during maturation, locks VP4 spikes in place, and undergoes Ca2+ withdrawal-induced dissociation during cell entry to trigger VP4 conformational changes for membrane penetration. The G3 serotype (e.g., rhesus rotavirus RRV) features two domains: a Rossmann fold (domain I, residues ~78-161 and 256-321) and a jelly-roll beta-sandwich (domain II, residues ~161-256), with four intrasubunit disulfide bonds and two Ca2+ sites per subunit interface. The outward-facing surface bears neutralizing epitopes (regions 7-1 and 7-2) targeted by protective antibodies, which bind trimeric VP7 to prevent uncoating; the inward-facing surface interacts with VP6 via N-terminal arms. VP7 is a principal immunogen for vaccines, with disulfide-linked trimers proposed as stable subunit candidates.[1][2][3][4]
Neutralizing antibodies stabilize VP7 trimer to inhibit uncoating and VP4 rearrangement
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rotavirus VP7 (G3 serotype) (VP7).